Literature DB >> 23903221

Therapeutic modulators of STAT signalling for human diseases.

Gabriella Miklossy1, Tyvette S Hilliard, James Turkson.   

Abstract

The signal transducer and activator of transcription (STAT) proteins have important roles in biological processes. The abnormal activation of STAT signalling pathways is also implicated in many human diseases, including cancer, autoimmune diseases, rheumatoid arthritis, asthma and diabetes. Over a decade has passed since the first inhibitor of a STAT protein was reported and efforts to discover modulators of STAT signalling as therapeutics continue. This Review discusses the outcomes of the ongoing drug discovery research endeavours against STAT proteins, provides perspectives on new directions for accelerating the discovery of drug candidates, and highlights the noteworthy candidate therapeutics that have progressed to clinical trials.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23903221      PMCID: PMC4038293          DOI: 10.1038/nrd4088

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  207 in total

Review 1.  Interleukin-4, interleukin-13, signal transducer and activator of transcription factor 6, and allergic asthma.

Authors:  Douglas A Kuperman; Robert P Schleimer
Journal:  Curr Mol Med       Date:  2008-08       Impact factor: 2.222

2.  Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts.

Authors:  Xiaolei Zhang; Peibin Yue; Brent D G Page; Tianshu Li; Wei Zhao; Andrew T Namanja; David Paladino; Jihe Zhao; Yuan Chen; Patrick T Gunning; James Turkson
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-23       Impact factor: 11.205

3.  A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells.

Authors:  Hui Song; Renxiao Wang; Shaomeng Wang; Jiayuh Lin
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-21       Impact factor: 11.205

Review 4.  Th1 versus Th17: are T cell cytokines relevant in multiple sclerosis?

Authors:  Amy E Lovett-Racke; Yuhong Yang; Michael K Racke
Journal:  Biochim Biophys Acta       Date:  2010-06-18

5.  Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice.

Authors:  Michelle A Blaskovich; Jiazhi Sun; Alan Cantor; James Turkson; Richard Jove; Saïd M Sebti
Journal:  Cancer Res       Date:  2003-03-15       Impact factor: 12.701

6.  TMC-264, a novel inhibitor of STAT6 activation produced by Phoma sp. TC 1674.

Authors:  Masaaki Sakurai; Maki Nishio; Kouzou Yamamoto; Toru Okuda; Kimio Kawano; Tetsuo Ohnuki
Journal:  J Antibiot (Tokyo)       Date:  2003-06       Impact factor: 2.649

7.  Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs).

Authors:  Anette Duensing; Fabiola Medeiros; Bryna McConarty; Nora E Joseph; Dipak Panigrahy; Samuel Singer; Christopher D M Fletcher; George D Demetri; Jonathan A Fletcher
Journal:  Oncogene       Date:  2004-05-13       Impact factor: 9.867

8.  Dual inhibition of Janus and Src family kinases by novel indirubin derivative blocks constitutively-activated Stat3 signaling associated with apoptosis of human pancreatic cancer cells.

Authors:  Sangkil Nam; Wei Wen; Anne Schroeder; Andreas Herrmann; Hua Yu; Xinlai Cheng; Karl-Heinz Merz; Gerhard Eisenbrand; Hongzhi Li; Yate-Ching Yuan; Richard Jove
Journal:  Mol Oncol       Date:  2012-11-16       Impact factor: 6.603

9.  A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells.

Authors:  Li Lin; Stephanie Deangelis; Elizabeth Foust; James Fuchs; Chenglong Li; Pui-Kai Li; Eric B Schwartz; Gregory B Lesinski; Don Benson; Jiagao Lü; Dale Hoyt; Jiayuh Lin
Journal:  Mol Cancer       Date:  2010-08-16       Impact factor: 27.401

10.  LLL-3 inhibits STAT3 activity, suppresses glioblastoma cell growth and prolongs survival in a mouse glioblastoma model.

Authors:  B Fuh; M Sobo; L Cen; D Josiah; B Hutzen; K Cisek; D Bhasin; N Regan; L Lin; C Chan; H Caldas; S DeAngelis; C Li; P-K Li; J Lin
Journal:  Br J Cancer       Date:  2009-01-13       Impact factor: 7.640

View more
  163 in total

Review 1.  The impact of the Cancer Genome Atlas on lung cancer.

Authors:  Jeremy T-H Chang; Yee Ming Lee; R Stephanie Huang
Journal:  Transl Res       Date:  2015-08-10       Impact factor: 7.012

Review 2.  Modulation of hepcidin to treat iron deregulation: potential clinical applications.

Authors:  Nicole L Blanchette; David H Manz; Frank M Torti; Suzy V Torti
Journal:  Expert Rev Hematol       Date:  2015-12-15       Impact factor: 2.929

Review 3.  Emerging cytokine networks in colorectal cancer.

Authors:  Nathan R West; Sarah McCuaig; Fanny Franchini; Fiona Powrie
Journal:  Nat Rev Immunol       Date:  2015-09-11       Impact factor: 53.106

Review 4.  STAT signaling in polycystic kidney disease.

Authors:  Sebastian Strubl; Jacob A Torres; Alison K Spindt; Hannah Pellegrini; Max C Liebau; Thomas Weimbs
Journal:  Cell Signal       Date:  2020-04-20       Impact factor: 4.315

Review 5.  Targeting IL4/IL4R for the treatment of epithelial cancer metastasis.

Authors:  Katherine Venmar Bankaitis; Barbara Fingleton
Journal:  Clin Exp Metastasis       Date:  2015-09-18       Impact factor: 5.150

Review 6.  Role of STAT3 in Genesis and Progression of Human Malignant Gliomas.

Authors:  Zangbéwendé Guy Ouédraogo; Julian Biau; Jean-Louis Kemeny; Laurent Morel; Pierre Verrelle; Emmanuel Chautard
Journal:  Mol Neurobiol       Date:  2016-09-22       Impact factor: 5.590

Review 7.  Interleukin-6: designing specific therapeutics for a complex cytokine.

Authors:  Christoph Garbers; Sylvia Heink; Thomas Korn; Stefan Rose-John
Journal:  Nat Rev Drug Discov       Date:  2018-05-04       Impact factor: 84.694

Review 8.  Targeting SH2 domains in breast cancer.

Authors:  Pietro Morlacchi; Fredika M Robertson; Jim Klostergaard; John S McMurray
Journal:  Future Med Chem       Date:  2014       Impact factor: 3.808

9.  Linker Variation and Structure-Activity Relationship Analyses of Carboxylic Acid-based Small Molecule STAT3 Inhibitors.

Authors:  Francisco Lopez-Tapia; Christine Brotherton-Pleiss; Peibin Yue; Heide Murakami; Ana Carolina Costa Araujo; Bruna Reis Dos Santos; Erin Ichinotsubo; Anna Rabkin; Raj Shah; Megan Lantz; Suzie Chen; Marcus A Tius; James Turkson
Journal:  ACS Med Chem Lett       Date:  2018-02-16       Impact factor: 4.345

10.  LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer.

Authors:  Li Pan; Xiang Chen; Shengling Fu; Wenying Yu; Chenglong Li; Tiffany Wang; Hui-Wen Lo; Jiayuh Lin
Journal:  Breast Cancer Res Treat       Date:  2020-04-02       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.